A carregar...
Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure
Hepatocellular carcinoma (HCC) is the main cause of death in patients with cirrhosis, with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Over time several randomized phase III trials have been performed testing sunitinib, brivanib, linifanib and other molecules...
Na minha lista:
| Publicado no: | World J Hepatol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4539398/ https://ncbi.nlm.nih.gov/pubmed/26301047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i17.2053 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|